WebDisclosure WebDisclosure
Basculer en Français
10837 Companies
235301 Keywords
164225 Articles
126039 Press releases
Headlines Articles Press releases Newron Pharmaceuticals S.p.A. Remove
  1. Home
  2. Companies
  3. Newron Pharmaceuticals S.p.A.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 03/17/2023 at 07:00, 3 years 4 months ago

    Newron to present at the 31st European Congress of Psychiatry  

    Logo of Newron Pharmaceuticals S.p.A.
  • PRESS RELEASE

    published on 03/14/2023 at 07:00, 3 years 5 months ago

    Newron announces 2022 financial results and provides outlook for 2023

    Logo of Newron Pharmaceuticals S.p.A.
  • PRESS RELEASE

    published on 02/16/2023 at 07:00, 3 years 6 months ago

    Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

    Logo of Newron Pharmaceuticals S.p.A.
  • PRESS RELEASE

    published on 01/03/2023 at 07:00, 3 years 7 months ago

    Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

    Logo of Newron Pharmaceuticals S.p.A.
Previous page
1 ... 10 11
Accesswire
  • Published on 08/15/2026 at 00:50, 1 day 22 hours ago

    Revive Therapeutics Reports Grant of Options

  • Published on 08/15/2026 at 00:15, 1 day 23 hours ago

    Full Circle Lithium Announces Closing of Private Placement

  • Published on 08/14/2026 at 23:45, 1 day 23 hours ago

    AI/ML Innovations Inc. Announces Proposed Private Placement

  • Published on 08/14/2026 at 23:25, 2 days ago

    NuRAN Wireless Closes $7.6 Million Financing

  • Published on 08/14/2026 at 23:00, 2 days ago

    Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

View all ACCESSWIRE
EQS Group
  • Published on 08/16/2026 at 19:40, 3 hours 49 minutes ago

    APIC delivers 55% EBITDA growth in the first half of 2026, reaching USD 44 million

  • Published on 08/16/2026 at 13:40, 9 hours 49 minutes ago

    Ajax says goodbye to Godts with a classy message in Paris: THE FUTURE BELONGS TO YOUNG GODTS

  • Published on 08/16/2026 at 09:45, 13 hours 44 minutes ago

    Ragnarok Zero: Global Set to Officially Launch on August 18

  • Published on 08/16/2026 at 06:15, 17 hours 14 minutes ago

    GARVEE met en avant les essentiels pour la maison et le jardin à l’approche de la transition entre la fin de l’été et le début de l’automne

  • Published on 08/16/2026 at 06:15, 17 hours 14 minutes ago

    Garvee Spotlights Home & Garden Essentials for the Late-Summer to Early-Autumn Transition

View all EQS
Les Echos
  • Published on 08/13/2026 at 18:00, 3 days 5 hours ago

    Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€

  • Published on 08/11/2026 at 17:45, 5 days 5 hours ago

    DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026

  • Published on 08/11/2026 at 17:40, 5 days 5 hours ago

    Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions

  • Published on 08/10/2026 at 18:00, 6 days 5 hours ago

    AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026

  • Published on 08/10/2026 at 18:00, 6 days 5 hours ago

    AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy